Alaunos Therapeutics
TCRT
154 hedge funds and large institutions have $328M invested in Alaunos Therapeutics in 2016 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 34 reducing their positions, and 20 closing their positions.
79% more call options, than puts
Call options by funds: $24.1M | Put options by funds: $13.4M
68% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 34
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
8% more funds holding
Funds holding: 143 → 154 (+11)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
20% less capital invested
Capital invested by funds: $408M → $328M (-$80.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.21M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.02M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.92M |
| 5 |
Millennium Management
New York
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$3.36M |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$2.51M |
| 3 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$2.14M |
| 4 |
Capital Fund Management (CFM)
Paris,
France
|
-$1.7M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.21M |
TCRT Hedge Fund Activity: Q2 2016 in Review
154 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2016, worth a combined $328M — down 20% from $408M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TCRT positions and 20 closed out — a net gain of 11 holders — while 57 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $14.2M. The largest seller was Miller Value Partners, cutting an estimated $3.36M.
- 154 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2016, up from 143 in Q1 2016.
- Funds reported $328M of Alaunos Therapeutics stock for Q2 2016, down 20% quarter-over-quarter.
- 31 funds opened new Alaunos Therapeutics positions in Q2 2016 and 20 closed out, a net change of +11 holders.
- The largest Alaunos Therapeutics buyer in Q2 2016 was Fidelity Investments, an estimated $14.2M added.
- The largest Alaunos Therapeutics seller in Q2 2016 was Miller Value Partners, an estimated $3.36M sold.
Based on aggregated 13F filings for Q2 2016.